Richard Brown is a Psychiatry physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8117 Preston Rd Ste 300
Dallas, TX 752256347
Telephone
469-998-4890Provider last certified this registry record 25 Aug 2024.
Clinical trials
- Intervening to Promote Tobacco Cessation Following Psychiatric Hospitalization
Sponsor: University of Texas at Austin
- Communication Training in Promoting Employment Retention Among Cancer Patients
Sponsor: Virginia Commonwealth University
- African American Cancer Clinical Trial Decisions: Testing Tailored Messages
Sponsor: Virginia Commonwealth University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CONMED CorporationProgram year20241 payment
- MEDLINE INDUSTRIES LPProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%SSRI100%Escitalopram Oxalate50%Fluoxetine Hcl50%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2014–2023 per NIH RePORTER. The latest:
- A Mobile-Delivered Personalized Feedback Intervention for Black Individuals who Engage in Hazardous Drinking
Health Behavior Solutions, Inc.
FY2023$275,550R41AA031398 - Brief Personalized Feedback Intervention for Latinx Hazardous Drinkers: A Community-Based Intervention
Health Behavior Solutions, Inc.
FY2022$259,522R41AA030227 - Culturally sensitive, evidence-based, Spanish language mobile app for smoking cessation for Latino cigarette smokers
Health Behavior Solutions, Inc.
FY2019$224,989R41DA048692
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”